| Literature DB >> 29426297 |
Reem Al Dossary1, Khaled R Alkharsah2, Haitham Kussaibi3.
Abstract
BACKGROUND: Breast cancer is considered the most common cancer in women worldwide and is the leading cause of cancer mortality. Sequences similar to Mouse Mammary Tumor Virus (MMTV) were detected in human breast cancer in several studies from different geographical areas. However, the role played by this virus in breast cancer tumorigenesis is not completely understood. These MMTV-like sequences were found to be associated with breast cancer of more malignant types. The aim of this study is to determine the prevalence of MMTV-like envelope gene (env) positivity in breast cancer and non-cancerous breast tissue from Saudi Arabia.Entities:
Keywords: Human breast cancer; Mouse mammary tumor virus; Prevalence
Mesh:
Year: 2018 PMID: 29426297 PMCID: PMC5810194 DOI: 10.1186/s12885-018-4074-6
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Schematic representation of the samples and study population
Fig. 2Alignment of MMTV and HTMV env sequences. The position of primers used in the study is underlined
Fig. 3Sensitivity of the newly designed primers for the detection of MMTV-env like sequences. A serial dilution of the positive control was used as template for the PCR reaction using MMTV F&R primers. Amplicon size is 187 bp. The numbers indicate the calculated copy number of the positive control fragment per microliter. Four microliters were used per reaction. Detection level is 250 copies per ml. (M) 100 bp DNA ladder
Fig. 4Samples positive for MMTV-env like sequences. A new DNA extraction was performed from all samples that gave a positive PCR result. The PCR reaction was repeated to confirm the results. (N) Stands for negative control
Frequency of MMTV env sequence in relation to age of patient, grade of cancer and lymph node metastasis
| Variables | frequency of MMTV | frequency of MMTV env positivity in tumor ( | frequency of MMTV env positivity in normal tissue ( | Total ( |
|---|---|---|---|---|
| Age (years) | ||||
| 20–29 | 0 | 0 | 0 | 0 |
| 30–39 | 1 (16.7%) | 0 | 1 (33.3%) | 2 (22.2%) |
| 40–49 | 1 (16.7%) | 0 | 2 (66.7%) | 3 (33.3%) |
| 50–59 | 3(50.0%) | 0 | 0 | 3 (33.3%) |
| 60–69 | 0 | 0 | 0 | 0 |
| 70–79 | 1 (16.7%) | 0 | 0 | 1 (11.1%) |
| | 0.35a | -(None reported as the observed positivity is zero) | 0.50a | 0.45a |
| Grade | ||||
| 1 | 0 | 0 | 1 (33.3%) | 1 (11.1%) |
| 2 | 2 (33.3%) | 0 | 2 (66.7%) | 4 (44.4%) |
| 3 | 4 (66.7%) | 0 | 0 | 4 (44.4%) |
| | 0.69a |
| 0.34a | 0.91a |
| Presence of lymph nodes metastasis | ||||
| No | 6(100.0%) | 0 | 2 (66.7) | 8 (88.9%) |
| Yes | 0 | 0 | 1(33.3%) | 1 (11.1%) |
| | 0.003a |
| 0.60a | 0.002a |
aFisher’s exact due to small numbers
MMTV positivity in the study population of different nationalities
| Nationality | Number of patients | MMTV positive patients/number of patients (%) | Region | MMTV positive patients/number of patients (%) |
|---|---|---|---|---|
| Pakistani | 1 | 0/1 (0) | Asian | 1/11 (9.1%) |
| Indian | 4 | 0/4 (0) | ||
| Philippines | 5 | 0/5 (0) | ||
| Sri Lankan | 1 | 1/1 (100) | ||
| Lebanese | 1 | 0/1 (0) | Middle East | 6/77 (7.8%) |
| Bahraini | 1 | 1/1 (100) | ||
| Palestinian | 2 | 0/2 (0) | ||
| Jordanian | 2 | 1/2 (50) | ||
| Saudi | 67 | 4/67 (5.97) | ||
| Syrian | 1 | 0/1 (0) | ||
| Yemini | 3 | 0/3 (0) | ||
| Somali | 1 | 0/1 (0) | Africa | 2/15 (13.3%) |
| Sudanese | 5 | 1/5 (20) | ||
| Egyptian | 8 | 0/8 (0) | ||
| Moroccan | 1 | 1/1 (100) | ||
| Total | 103 | 9/103 (8.7) | 9/103 (8.7) |
Fig. 5Alignment of the detected MMTV-like env sequences (MTVF5, 13, 58, 59,104,147,195,204) shows very high similarity to HMTV
Prevalence of MMTV like env sequence in human breast cancer samples and controls in published articles between 1995 and 2014 from different geographical location
| Year | Geographic location | Breast cancer samples | Control samples | Reference | ||
|---|---|---|---|---|---|---|
| Number | MMTV-like | Number | MMTV-like | |||
| 1995 | USA | 314 | 121 (38.5%) | 136 | 4 (2.9%) | [ |
| 2000 | USA | 72 | 27 (37%) | 35 | 0 (0%) | [ |
| 2001 | USA | 106 | 32 (30.1%) | 106 | 1 (0.94) | [ |
| 2003 | Australia | 45 Caucasian Australian, 120, Vietnamese | 19 (42.2%) Caucasian Australian, 1(0.8%), Vietnamese | 111 Australian and 60 Vietnamese (normal breast tissues) | 2 (1.8%) Australian and 0 (0%) Vietnamese | [ |
| 2004 | Australia | 128 | 50 (40%) | – | – | [ |
| 2004 | Australia | 136 | 43 (32%) | 164 | 15 (9%) | [ |
| 2004 | Tunisia | 38 | 28 (73%) | – | – | [ |
| 2006 | Italy | 45 | 15 (33%) | 40 | 0 | [ |
| 2007 | Mexico | 119 | 5 (4.2%) | – | – | [ |
| 2008 | Australia | 50 | 28 (56%) | – | – | [ |
| 2008 | Tunisia | 122 | 17 (13.9%) | 122 | 0 (0%) | [ |
| 2008 | Japan | 46 | 0 (0%) | 3 benign breast tumor | 0 (0%) | [ |
| 2010 | Australia | 74 | 33 (45%) | 29 | 0 (0%) | [ |
| 2011 | Australia | 42 | 0 (0%) | – | – | [ |
| 2012 | Australia | 50 | 39 (78%) | 40 | 8 (32%) | [ |
| 2012 | Iran | 50+ 300 blood from breast cancer patient | 0 (0%) | 300 | 0 (0%) | [ |
| 2013 | Mexico | 86 | 0 (0%) | 65 | 0 (0%) | [ |
| 2013 | Iran | 40 | 0 (0%) | – | – | [ |
| 2014 | Mexico | 458 | 57 (12.4%) | 458 | 72 (15.7%) | [ |
| 2014 | Pakistan | 80+ 80 paired blood samples | 16 (20%) | – | – | [ |
| 2014 | Morocco | 42 | 24 (57%) | 18 (matched normal breast tissue from safety margins) | 6 (33.3%) | [ |
| 2017 | Pakistan | 250 samples | 29.3% | – | – | [ |
| 2017 | Myanmar | 58 samples | 1 (1.7%) | – | – | [ |